source
- Roche signs $1.2 bn obesity partnership with China's Rona Therapeutics, paying up to $100 m upfrontRoche announced its seventh China deal this year, partnering with RNA‑interference specialist Rona Therapeutics to target obesity. The collaboration licenses an ALK7 inhibition asset and includes…
- BioNTech’s mRNA cancer vaccine misses key endpoint in head-and-neck trial, study to continueBioNTech reported that its mRNA cancer immunotherapy BNT113 did not improve progression‑free survival when added to Keytruda in patients with HPV16‑positive head and neck squamous cell carcinoma. T…